| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Human Immunogenetics Program, Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; and
Department of Medicine, University of Washington, Seattle, WA 98195
The costimulatory molecules B7-1 and B7-2 regulate T cell activation by delivering activation signals through CD28 and inhibitory signals through CTLA4. Graft-vs-host disease (GVHD) is caused by activated donor T cells. Previously, we showed that CD28-deficient donor T cells induced less-severe GVHD than wild-type donor T cells, suggesting that CD28 signals exacerbate GVHD. In this paper we demonstrate that CTLA4 signals attenuate the severity of GVHD. Targeting the CD28 receptor with a specific mAb modulates the receptor in vivo, inhibits donor T cell expansion, and prevents GVHD. CTLA4 signaling was necessary for this effect because treatment with a soluble ligand that blocks binding of B7 to both CD28 and CTLA4 did not prevent GVHD as effectively as anti-CD28 mAb. These results support the current model of T cell costimulation in which CD28 signals amplify GVHD while CTLA4 signals inhibit GVHD, providing evidence that selective targeting of CD28 might be a better therapeutic strategy for inducing immunological tolerance than blocking the ligands for both CD28 and CTLA4.
This article has been cited by other articles:
|
|
 |
|
  G. Socie and B. R. Blazar Acute graft-versus-host disease: from the bench to the bedside Blood, November 12, 2009; 114(20): 4327 - 4336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Guillonneau, C. Seveno, A.-S. Dugast, X.-L. Li, K. Renaudin, F. Haspot, C. Usal, J. Veziers, I. Anegon, and B. Vanhove Anti-CD28 Antibodies Modify Regulatory Mechanisms and Reinforce Tolerance in CD40Ig-Treated Heart Allograft Recipients J. Immunol., December 15, 2007; 179(12): 8164 - 8171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Z. Yu, Y. Liang, R. I. Nurieva, F. Guo, C. Anasetti, and C. Dong Opposing Effects of ICOS on Graft-versus-Host Disease Mediated by CD4 and CD8 T Cells. J. Immunol., June 15, 2006; 176(12): 7394 - 7401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R Blazar and W. J Murphy Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD) Phil Trans R Soc B, September 29, 2005; 360(1461): 1747 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Albert, X.-Z. Yu, P. J. Martin, and C. Anasetti Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin Blood, February 1, 2005; 105(3): 1355 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Vanhove, G. Laflamme, F. Coulon, M. Mougin, P. Vusio, F. Haspot, J. Tiollier, and J.-P. Soulillou Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-{alpha}1-antitrypsin fusion antibody Blood, July 15, 2003; 102(2): 564 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Z. Yu, P. J. Martin, and C. Anasetti CD28 Signal Enhances Apoptosis of CD8 T Cells After Strong TCR Ligation J. Immunol., March 15, 2003; 170(6): 3002 - 3006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, J. G. Heuer, S. Na, E. Galbreath, T. Zhang, D. D. Yang, A. Glasebrook, and H. Y. Song Accelerated Onset and Increased Severity of Acute Graft-Versus-Host Disease Following Adoptive Transfer of DR6-Deficient T Cells J. Immunol., October 1, 2002; 169(7): 3993 - 3998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tan, D. A. Mitchell, T. N. Buss, M. A. Holmes, C. Anasetti, and J. Foote "Superhumanized" Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28 J. Immunol., July 15, 2002; 169(2): 1119 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Lang, P. Nguyen, R. Peach, W. C. Gause, and C. S. Via In Vivo CD86 Blockade Inhibits CD4+ T Cell Activation, Whereas CD80 Blockade Potentiates CD8+ T Cell Activation and CTL Effector Function J. Immunol., April 15, 2002; 168(8): 3786 - 3792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Haspot, F. Villemain, G. Laflamme, F. Coulon, D. Olive, J. Tiollier, J.-P. Soulillou, and B. Vanhove Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses Blood, March 15, 2002; 99(6): 2228 - 2234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Matsue, K. Matsue, M. Kusuhara, T. Kumamoto, K. Okumura, H. Yagita, and A. Takashima Immunosuppressive properties of CD95L-transduced "killer" hybrids created by fusing donor- and recipient-derived dendritic cells Blood, December 1, 2001; 98(12): 3465 - 3472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kobayashi, E. Azuma, M. Ido, M. Hirayama, Q. Jiang, S. Iwamoto, T. Kumamoto, H. Yamamoto, M. Sakurai, and Y. Komada A Pivotal Role of Rho GTPase in the Regulation of Morphology and Function of Dendritic Cells J. Immunol., October 1, 2001; 167(7): 3585 - 3591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Taylor, C. J. Lees, H. Waldmann, R. J. Noelle, and B. R. Blazar Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions Blood, July 15, 2001; 98(2): 467 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Z. Yu, S. J. Bidwell, P. J. Martin, and C. Anasetti Anti-CD3{{epsilon}} F(ab')2 Prevents Graft-Versus-Host Disease by Selectively Depleting Donor T Cells Activated by Recipient Alloantigens J. Immunol., May 1, 2001; 166(9): 5835 - 5839. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
